**Abstract:** Sarcoidosis is a granulomatous disease that most frequently affects the lungs with pulmonary infiltrates and/or bilateral hilar and mediastinal lymphadenopathy. An association of sarcoidosis and lymphoproliferative disease has previously been reported as the sarcoidosis-lymphoma syndrome. Although this syndrome is characterized by sarcoidosis preceding lymphoma, very few cases of sarcoidosis following lymphoma have been reported. We describe the clinical, biological, and radiological characteristics and outcome of 39 patients presenting with sarcoidosis following lymphoproliferative disease, including 14 previously unreported cases and 25 additional patients, after performing a literature review. Hodgkin lymphoma and non-Hodgkin lymphoma were equally represented. The median delay between lymphoma and sarcoidosis was 18 months. Only 16 patients (41%) required treatment. Sarcoidosis was of mild intensity or self-healing in most cases, and overall clinical response to sarcoidosis was excellent with complete clinical response in 91% of patients. Sarcoidosis was identified after a follow-up computerized tomography scan (CT-scan) or $^{18}$fluorodeoxyglucose-positron emission tomography/ computerized tomography ($^{18}$FDG-PET/CT) evaluation in 18/34 patients (53%). Sarcoidosis is therefore a differential diagnosis to consider when lymphoma relapse is suspected on a CT-scan or $^{18}$FDG-PET/CT, emphasizing the necessity to rely on histological confirmation of lymphoma relapse.

(Medicine 93(21)e121)

**Abbreviations:** ACE = angiotensin-converting enzyme, ATS = American Thoracic Society, BMT = bone marrow transplantation, CR = complete response, CT-scan = computerized tomography scan, DLBCL = diffuse large B-cell lymphoma, ERS = European Respiratory Society, $^{18}$FDG-PET/CT = $^{18}$fluorodeoxyglucose-positron emission tomography/computerized tomography, HCQ = hydroxychloroquine, HL = Hodgkin lymphoma, HSCT = hematopoietic stem cell transplant, LDH = lactate dehydrogenase, NHL = non-Hodgkin lymphoma, NSAID = nonsteroidal anti-inflammatory drugs, PR = partial response, WASOG = World Association of Sarcoidosis and Other Granulomatous Disorders.

---

**INTRODUCTION**

Sarcoidosis is a multisystem disease of unknown origin, characterized by the presence of noncaseating epithelioid cell granulomas. It frequently presents in young and middle-aged adults with pulmonary infiltrates and with bilateral hilar and mediastinal lymphadenopathy, and more rarely the eye, the liver, the spleen, the kidneys, and the heart. The diagnosis of sarcoidosis is based on criteria from the American Thoracic Society (ATS), the European Respiratory Society (ERS), and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). These criteria include the presence of clinical-radiological findings suggestive of sarcoidosis, the presence of histological evidence of noncaseating epithelioid cell granulomas, and the exclusion of known causes of granulomatous reactions.

The association of sarcoidosis and lymphoma is well established and was named the sarcoidosis-lymphoma syndrome by Brincker in 1986. In this syndrome, lymphoma occurs after sarcoidosis, and patients often have a chronic active form of sarcoidosis, suggesting that chronic disease could be a risk factor for lymphoma. This finding is supported by the demonstration of an increased risk of Hodgkin lymphoma (HL) of 14.1% in patients with sarcoidosis in a population-based case–control study in Scandinavia.

In addition, granulomatous reactions are frequently associated with lymphoma. Such sarcoid-like reactions have
been reported to occur in up to 13.8% of patients with HL and 7.3% of patients with non-Hodgkin lymphomas (NHL). The granulomatous reaction is most often seen in the same lymph node or organ as the lymphoma but can be found in other hematopoietic organs. Sarcoid-like reactions can sometimes be the predominant histological finding with few tumor cells, especially in HL or T-cell lymphomas, making diagnosis of lymphoproliferative disorder difficult.

The sarcoidosis-lymphoma syndrome is a well characterized association, but the onset of sarcoidosis after the lymphoma has only rarely been reported in the literature. It is not known whether the association is fortuitous or not.

In the present study, we describe the clinical, biological, and radiological characteristics and the outcome of patients presenting with sarcoidosis occurring after lymphoma. We report the largest published series so far of 14 cases and review the literature.

**PATIENTS AND METHODS**

**Patients**

We conducted a French national retrospective study in hematology and internal medicine departments. Patients were included if they were >18 years of age and diagnosed with HL or NHL that preceded the onset of sarcoidosis. The diagnosis of sarcoidosis was defined by the association of clinical and radiological findings suggestive of sarcoidosis with histological confirmation, according to the ATS/ERS/WASOG criteria. Histological samples were obtained from tissue biopsies of lymph nodes (n = 12), bone marrow (n = 1), lung (n = 1), bronchial wall (n = 1), skin (n = 1), or minor salivary glands (n = 2), and characterized by noncaseating epithelioid cell granulomatous lesions without evidence of mycobacterial infection. Other specific granulomatous disorders were excluded. Serum protein electrophoresis was systematically performed to exclude common variable immunodeficiency (CVID). Patients with concomitant sarcoidosis and lymphoma or with evidence of granulomatosis on tissue biopsy at lymphoma onset were also excluded. Diagnosis of lymphoproliferative disorder was based on the World Health Organization classification criteria. All lymphoproliferative disorders were confirmed by tissue biopsy. A total of 14 patients with sarcoidosis occurring after lymphoma were included. This survey was conducted in compliance with the protocol of Good Clinical Practices and the Declaration of Helsinki principles.

**Clinical and Laboratory Assessment**

Clinical and biological data were retrieved for each patient at the time of the lymphoma diagnosis, diagnosis of sarcoidosis, during follow-up, and at the end of follow-up, by J.L. and the practitioners in charge of the patients using a standardized form. Collected data included sex, age at diagnosis of lymphoma and sarcoidosis, lymphoma characteristics, treatment received for lymphoma and outcome, characteristics of sarcoidosis at diagnosis and during follow-up, and treatment received for sarcoidosis and outcome. Imaging findings and \(^{18}\)fluorodeoxyglucose positron emission tomography/computed tomography (\(^{18}\)FDG-PET/CT) characteristics of lymphoma and sarcoidosis were recorded when available. Laboratory assessment included serum electrophoresis and immunofixation, serum creatinine level, lactate dehydrogenase (LDH), calcium, angiotensin-converting enzyme (ACE), albumin, C-reactive protein, and complete blood count.

**Outcome and Response to Therapy**

Hematological response after treatment of lymphoma was defined as complete response (CR), partial response (PR), and relapse according to the proposed International Workshop Criteria (Cheson criteria).

Regarding sarcoidosis, clinical complete response (CR) was defined by a complete regression of clinical symptoms and clinical PR by a decrease ≥50% of the initial symptoms intensity, without onset of new clinical manifestations. Radiological CR was characterized by normalization of the \(^{18}\)FDG-PET/CT or of the CT-scan, and radiological PR by a ≥50% reduction in the size of the initial lesions or lymph nodes and the absence of new radiological findings related to sarcoidosis.

**Review of the Literature**

We systematically reviewed the literature for reports of characteristics and clinical outcomes of patients with sarcoidosis occurring after lymphoma diagnosis.

We searched MEDLINE via PubMed for all articles published in English or French using the keywords or MeSH terms “sarcoidosis,” “lymphoma,” “non-Hodgkin lymphoma,” “Hodgkin,” “granulomatous reaction,” and “granuloma.” We reviewed bibliographies of articles retrieved for other relevant articles. Only reports with available clinical, biological, radiological, and histological data and outcomes were included. Reports in which the order of occurrence between sarcoidosis and lymphoproliferative disorder was unknown were excluded. Relevant data were recorded using the same standardized form as for our personal series.

**Statistical Analysis**

Descriptive statistics included the mean (SD) or median (minimum–maximum) as appropriate for continuous variables and frequency (percentage) for categorical variables.

**RESULTS**

**Characteristics of Patients**

We identified 17 patients from 7 different centers who were eligible for the study. Diagnosis of sarcoidosis was made between October 2006 and October 2013. All patients had a history of lymphoma prior to sarcoidosis. Fourteen patients fulfilled the inclusion and exclusion criteria, whereas 3 patients were excluded (1 patient received interferon therapy for melanoma prior to sarcoidosis onset, 1 patient had peripheral neuropathy as the only clinical symptom finally attributed to cryoglobulinemia complicating lymphoplasmacytic lymphoma, and 1 patient who had a history of tuberculosis and necrosis accompanying granuloma in the bone marrow biopsy).

Review of the literature identified 21 studies, including 36 patients with sarcoidosis occurring after lymphoma diagnosis. Eleven patients were excluded for lack of data and the 25 remaining patients were included. Combining our personal series and the literature review, 39 patients were analyzed.

The characteristics of the 14 cases from our study and the 25 patients from the literature are shown in Tables 1 and 2, respectively.

**Characteristics of Lymphoma**

Main characteristics of lymphoma diagnosis, treatment, and outcome are detailed in Tables 1 and 2 and summarized in Table 3. Median age at lymphoma diagnosis was 45 years.
| Case No. | Sex | Age at Lymphoma/Sarcoidosis Onset | Interval to Sarcoidosis, mo | Lymphoma Characteristics | Sarcoïdosis Characteristics |
|----------|-----|----------------------------------|-----------------------------|---------------------------|-----------------------------|
|          |     |                                  |                             | Type/Stage | Treatment | Relapse/ Treatment | Clinical Manifestation | Radiological and PET/CT Findings | Localization of Granuloma on Biopsy | Treatment/Duration, mo | Clinical/Radiological Response | Relapse Follow-Up, mo |
| 1        | M   | 56/56                            | 8                           | DLBCL/4A | R-CHOP   | No              | None                  | Hypermetabolic hilar and mediastinal LN, PI | Mediastinal LN | None | CR/PR | No | 9  |
| 2        | F   | 20/27                            | 84                          | HL/1B    | RT, CT    | No              | Panuveitis, arthralgia, weight loss, diaphoresis | Mediastinal LN, MSG | Pred. (0.5 mg/kg)/ongoing | CR/PR | No | 8   |
| 3        | F   | 43/71                            | 329                         | HL/4A    | MOPP-ABV, RT | Yes*/Rituximab | Anterior uveitis | Hypermetabolic hilar and mediastinal LN, PI | Bronchial wall, MSG | Topical steroids | CR/NR | No | 12  |
| 4        | F   | 45/53                            | 95                          | DLBCL/4BX | R-ACVBP, MTXHD, HSCT ABVD, RT | No | Diaphoresis | Hypermetabolic hilar and mediastinal LN, PI | Supraclavicular LN | None | CR/CR | No | 8   |
| 5        | F   | 33/40                            | 87                          | HL/2A    | ABVD      | Yes*/ MINE, ESHAP, double HSCT | Diaphoresis | Hypermetabolic hilar and mediastinal LN | Mediastinal LN | None | CR/NR | No | 48  |
| 6        | F   | 30/34                            | 51                          | HL/4B    | ABVD      | Yes*/ MINE, ESHAP, ESHAP, double HSCT | Arthralgia, subcutaneous nodules, panniculitis | Mediastinal LN | Pred. (0.5 mg/kg)/8 | CR/CR | No | 49  |
| 7        | F   | 49/50                            | 10                          | DLBCL/4A | R-CHOP, HSCT | No | None | Hypermetabolic hilar and mediastinal LN | Mediastinal LN | None | CR/PR | No | 67  |
| 8        | M   | 60/63                            | 31                          | DLBCL/4A | R-CHOP, HSCT | No | None | Hypermetabolic mediastinal LN | Mediastinal LN | None | CR/NR | No | 11  |
| 9        | M   | 49/51                            | 24                          | MCL/4B   | R-CHOP, TBI, HSCT | No | Skin lesions | Diffuse hypermetabolic mediastinal LN | Mediastinal LN, skin, BM | None | NR/NR | No | 42  |
| 10       | M   | 36/42                            | 80                          | HL/3A    | Stanford V | Yes†/ ESHAP, HSCT | Arthralgia | Mediastinal LN | Mediastinal LN | None | CR/CR | No | 84  |
| 11       | F   | 42/44                            | 20                          | HL/1A    | MOPP-ABV, RT | No | None | Mediastinal LN | Mediastinal LN | None | CR/NR | No | 96  |

(Continued)
| Case No. | Sex | Age at Lymphoma/Sarcoidosis Onset | Interval to Sarcoidosis, mo | Type/Stage | Treatment | Relapse/Treatment | Clinical Manifestation | Radiological and PET/CT Findings | Localization of Granuloma on Biopsy | Treatment/Duration, mo | Clinical/Radiological Response | Relapse | Follow-Up, mo |
|----------|-----|----------------------------------|-----------------------------|------------|-----------|-----------------|-----------------------|-------------------------------|--------------------------------|---------------------------|---------------------------|---------|-------------|
| 12       | F   | 48/49                            | 11                          | DLBCL/2A   | R-CHOP, R-DHAP, MTXHD | No               | Arthralgia           | Hypermetabolic hilar, mediastinal and retroperitoneal LN | Retroperitoneal LN             | HCQ and NSAID/ongoing     | NR/NA       | No          | 3        |
| 13       | F   | 26/27                            | 19                          | HL/3       | ABVD, RT | Yes*/MINE, double HSCT | Cough, fever, diaphoresis, dyspnea, myelitis, meningitis | Mediastinal LN, PI, myelitis, meningitis | OLB                            | Pred.; CYS¹/10; MTX²/ongoing and Pred.²/ongoing | CR/CR       | Yes         | 120      |
| 14       | H   | 63/70                            | 85                          | HL/2       | ABVD     | Yes*/R-ICE, HSCT | Weight loss, splenomegaly | Diffuse hypermetabolic LN | ITLN                          | Pred. (0.5 mg/kg)/6         | CR/CR       | No          | 8        |

ABVD = Adriamycin, Bleomycin, Vinblastine, Dacarbazine, ACVBP = Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone, BM = bone marrow, CHOP = Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone, CR = complete response, CT = nonspecified chemotherapy, CYS = Cyclophosphamide, DHAP = Dexamethasone, Cytarabine, Cisplatin, DLBCL = diffuse large B-cell lymphoma, ESHAP = Etoposide, methyprednisolone, Cytarabine, Cysplatin, HCQ = hydroxychloroquine, HL = Hodgkin lymphoma, HSCT = autologous hematopoietic stem cell transplant, ICE = Ifosfamide, Carboplatin, Etoposide, ITLN = intrathoracic lymph nodes, LN = lymph nodes, MCL = mantle cell lymphoma, MINE = Mesna, Ifosfamide, Novantrone, Etoposide, MOPP-ABV = Mechlorethamine, Oncovin, Procarbazine, Prednisone—Adriamycin, Bleomycin, Vinblastine, MSG = minor salivary glands, MTX = methotrexate, MTXHD = methotrexate high dose, NA = not available, NR = nonresponse, NSAID = nonsteroidal anti-inflammatory drugs, OLB = open lung biopsy, PI = pulmonary infiltrates, PR = partial response, Pred. = oral prednisone, R = Rituximab, RT = radiotherapy, Stanford V = Doxorubicin, Vinblastine, Mechlorethamine, Vincristine, Bleomycin, Etoposide, Prednisone, TBI = total body irradiation.

*Relapse prior to sarcoidosis onset.
²Relapse after sarcoidosis onset.
³At relapse.
⁴Lymphoma relapsed as a DLBCL localized to the tonsils.
| Reference | Case No. | Sex | Age at Lymphoma/Sarcoidosis Onset | Interval to Sarcoidosis, mo | Type/Stage | Treatment | Relapse/Treatment | Clinical Manifestation | Radiological and PET/CT Findings | Localisation of Granuloma on Biopsy | Treatment/Duration, mo | Clinical/Radiological Response | Relapse | Follow-Up, mo |
|-----------|---------|-----|-----------------------------------|-----------------------------|------------|-----------|------------------|-----------------------|-------------------------------|-------------------------------|------------------------|-----------------------------|---------|--------------|
| Kornacker et al 9 | 15 | M | 44/44 | ≈2.5 | FL/4A | R-CHOP | Yes/NA | Dyspnea, asthenia, fever | PI | TBLB | None | CR/PR | No | 12 |
| Kornacker et al 9 | 16 | M | 41/41 | ≈10 | DLBCL/3BS | CHOEP, HSCT | No | Fever, arthralgia, EN | Mediastinal LN | Skin, BM | Pred. (40 mg)/NA | CR/CR | No | 6 |
| Gooneratne et al 10 | 17 | F | 52/53 | 12 | FL/NA | Chlorambucil | HGT | Uveitis | Lung involvement | NA | None | CR/CR | No | 169 |
| Gooneratne et al 10 | 18 | F | 50/51 | 12 | HL/4 | CLOPP | No | NA | Lung involvement | NA | None | CR/CR | No | 346 |
| Maayan et al 11 | 19 | M | 16/23 | 84 | HL/3 | eBEACOPP, ABVD | No | Inguinal LN, hypercalcemia | Mediastinal LN | TBLB, LN | Pred./NA | CR/NA | No | NA |
| Maayan et al 11 | 20 | F | 57/57 | 6 | HL/4 | eBEACOPP | No | None | Mediastinal LN | MLN | None | CR/NA | No | NA |
| Maayan et al 11 | 21 | F | 44/45 | 12 | DLBCL/4 | R-CHOP, RT | No | None | PI | TBLB | ICS/NA | CR/CR | No | NA |
| Maayan et al 11 | 22 | F | 47/49 | ≈36 | DLBCL/NA | CT, HSCT | No | None | Mediastinal LN | MLN | Pred., ICS/NA | NA/NA | No | NA |
| De Hemicourt et al 12 | 23 | F | 27/59 | 390 | HL/2B | RT | No | EN, disseminated LN, weight loss, diaphoresis, acute congestive heart failure, pericarditis, cardiac arrhythmias | Diffuse hypermetabolic LN, PI, cardiomegaly | LN | Pred. (1 mg/kg)/NA; AZA (150 mg)/NA | CR/NA | Yes | 9 |
| Li et al 13 | 24 | F | 23/25 | 21 | HL/3A | ABVD | Yes/CT | None | Hypermethylated hilar, mediastinal LN | Hypermethylated hilar, mediastinal and porta hepatitis LN | MLN | None | CR/NR | No | 10 |
| Li et al 13 | 25 | F | 63/64 | 14 | DLBCL/1B | R-CHOP | No | Hypermethylated hilar, mediastinal LN | Hypermethylated hilar, mediastinal and porta hepatitis LN | MLN and lacrimal glands | Pred. (40 mg)/NA | CR/CR | No | 44 |

(Continued)
| Reference          | Case No. | Sex | Age at Onset | Interval to Onset | Lymphoma Characteristics | Relapse/ Treatment | Sarcoïdosis Characteristics | Localisation of Granuloma on Biopsy | Treatment/ Duration, mo | Clinical/ Radiological Response | Relapse | Follow-Up, mo |
|--------------------|---------|-----|--------------|-----------------|--------------------------|--------------------|-----------------------------|-----------------------------------|------------------------|---------------------------------|---------|---------------|
| Subbiah et al14    | 26      | F   | 32/32        | 11              | HL/4B                    | ABVD               | No                          | EN                               | MLN                    | Pred. (20 mg)/NA                | CR/CR   | 18            |
| Fallanca et al15   | 27      | F   | 27/28        | 24              | HL/3B                    | ABVD               | Yes*/ IGEV, RT, HSCT        | None                             | BM                     | None                            | CR/CR   | 12            |
| Suen et al16       | 28      | F   | 28/37        | 108             | HL/3B                    | CT                 | Yes*/CT                     | None                             | PI                     | TBLB                            | CR/NA   | No            |
| Suen et al16       | 29      | F   | 33/33        | 7               | HL/3B                    | CT                 | No                          | Dyspnea, cough                  | PI, hilar LN           | OLB                              | CR/NA   | No            |
| Suen et al16       | 30      | M   | 46/47        | 10              | NHL/4                    | CT                 | No                          | Dyspnea, cough, fever, weight loss, arthritis | Hilar LN  | OLB              | Pred./NA | No            |
| Suen et al16       | 31      | M   | 28/30        | 28              | TCL/NA                   | CT, TBI, BMT       | No                          | Dyspnea, cough, weight loss     | Hilar LN, PF | OLB              | Pred./NA | NR/NA1 | 281        |
| Sawhney et al18    | 32      | M   | 34/35        | 18              | HL/NA                    | COPP-ABV           | No                          | Ichthyosis, subcutaneous nodules | Normal chest CT-scan | Skin                           | None     | NA/CR         |
| Sonet et al20      | 33      | F   | 66/68        | 27              | TFL/NA                   | CHOP, RT           | No                          | Cervical LN, jugal tumefaction | Hypermetabolic nasal fossa, jugal zones, pulmonary parenchyma | Jugal mass| None/NA/NA      | NA       | 52            |
| Paydas et al21     | 34      | M   | 54/55        | 10              | HL/4B                    | ABVD               | Yes*/ DHAP                   | None                             | Pulmonary parenchyma 18FDG uptake | TBLB     | Pred. (1 mg/ kg)/ l | CR/CR   | 7             |
| Nakamura et al23   | 35      | F   | 56/57        | 12              | DLBCL/4                  | CT, total gastrectomy | No                          | Intramuscular mass              | Right lateral vastus muscle mass | Muscle  | None          | CR/NA   | 36            |
| Farrell et al25     | 36      | M   | 50/50        | 1               | TCL/3B                   | CT                 | No                          | Skin lesions                    | Pulmonary parenchyma 18Ga uptake | Skin    | None          | CR/NA   | 6             |
## TABLE 2. (Continued)

| Reference | Case No. | Sex | Age at Lymphoma/Sarcoidosis Onset | Interval to Sarcoidosis, mo | Type/Stage | Treatment | Relapse/Treatment | Clinical Manifestation | Radiological and PET/CT Findings | Localisation of Granuloma on Biopsy | Treatment/Duration, mo | Clinical/Radiological Response | Relapse | Follow-Up, mo |
|-----------|----------|-----|-----------------------------------|---------------------------|------------|-----------|-------------------|------------------------|-----------------------------------|------------------------------------|--------------------------|--------------------------|---------|-------------|
| Ozer et al<sup>26</sup> | 37 | F | 56/56 | ≥7 | HL/1A | ABVD, RT | No | Dyspnea | Hypermetabolic hilar and mediastinal LN, pleura, pulmonary parenchyma | MLN | Pred./NA | NA/NA | No | NA |
| Ozer et al<sup>26</sup> | 38 | F | 49/49 | ≥6 | DLBCL/3A | R-CHOP | No | None | Hypermetabolic abdominal and mediastinal LN | MLN | None | CR/NA | No | NA |
| Hollister et al<sup>27</sup> | 39 | F | 56/56 | ≥6 | DLBCL/4 | R-CHOP | No | None | Hypermetabolic mediastinal LN | MLN | None | CR/NA | No | NA |

<sup>2</sup>= approximately, ABVD = Adriamycin, Bleomycin, Vinblastine, Dacarbazine, AZA = azathioprine, BM = bone marrow, BMT = allogenic bone marrow transplantation, CHOP = Cyclophosphamide, Hydroxydaunorubicin, Vincristine, Etoposide, Prednisone, CHOP = Cyclophosphamide, Hydroxydaunorubicin, Vincristine, Prednisone, CLOPP = Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, COPP-ABV = Cyclophosphamide, Oncovin, Procarbazine, Prednisone—Adriamycin, Bleomycin, Vinblastine, CR = complete response, CT = nonspecified chemotherapy, DHAP = Dexamethasone, Cytarabine, Cisplatin, DLBCL = diffuse large B-cell lymphoma, eBEACOPP = escalated Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, EN = erythema nodosum, FDG = fluorodeoxyglucose, FL = follicular lymphoma, HGT = high-grade transformation, HL = Hodgkin lymphoma, HSCT = autologous hematopoietic stem cell transplant, ICS = inhaled corticosteroids, IGEV = Ifosfamide, Gemcitabine, Vinorelbine, Prednisone, LN = lymph nodes, MLN = mediastinal lymph node, NA = not available, NHL = non-Hodgkin lymphoma, NR = non response, OLB = open lung biopsy, PI = pulmonary infiltrates, PF = pulmonary fibrosis, PR = partial response, Pred. = oral prednisone, R = rituximab, RT = radiotherapy, TBI = total body irradiation, TCL = T-cell lymphoma, TBLB = transbronchial lung biopsy, TFL = transformed follicular lymphoma.

*Relapse prior to sarcoidosis onset.
†Relapse after sarcoidosis onset.
‡At relapse.
§Lymphoma relapsed as NHL.
Dead on last follow-up.
TABLE 3. Summary of Patient Characteristics From Our 14 Patients and From the Literature Review

|                          | Our Patients (n = 14) | Literature Review (n = 25) | All Patients (n = 39) |
|--------------------------|-----------------------|---------------------------|-----------------------|
| **Men/women, n (%)**     | 5 (35.7%)/9 (64.3%)   | 8 (32%)/17 (68%)          | 13 (33.3%)/26 (66.6%)|
| **Lymphoma characteristics** |                       |                           |                       |
| Age at diagnosis, median | 44.6                  | 46                        | 45.4                  |
| Type of lymphoma         |                       |                           |                       |
| HL, n (%)                | 8 (57.1%)*            | 12 (48%)*                 | 20 (51.3%)            |
| NHL, n (%)               | 7 (50%)*              | 14 (56%)*                 | 21 (53.8%)            |
| B-cell NHL, n (%)        | 6 (42.9%)             | 10 (40%)                  | 16 (41%)              |
| DLBCL, n (%)             | 5 (35.7%)             | 7 (28%)                   | 12 (30.8%)            |
| Other B-cell NHL, n (%)  | 1 (7.1%)              | 3† (12%)                  | 4† (10.3%)            |
| TCL, n (%)               | 0 (0%)                | 2 (8%)                    | 2 (5.1%)              |
| Lymphoma stage 3 or 4, n (%) | 9 (64.2%)            | 17/21 (80.9%)             | 26/35 (74.3%)         |
| **Treatment (prior to sarcoidosis only)** |                       |                           |                       |
| Radiotherapy treatment, n (%) | 6 (42.9%)            | 6 (24%)                   | 12 (30.7%)            |
| Rituximab treatment, n (%) | 8 (57.1%)            | 5 (20%)                   | 13 (33.3%)            |
| HSCT, n (%)              | 7 (50%)               | 3 (12%)                   | 10 (25.6%)            |
| BMT, n (%)               | 0 (0%)                | 1 (4%)                    | 1 (2.6%)              |
| **Response to treatment** |                       |                           |                       |
| CR                       | 12 (85.7%)            | 24 (96%)                  | 36 (92%)              |
| PR                       | 2 (14.3%)             | 1 (4%)                    | 3 (7.7%)              |
| NR                       | 0 (0%)                | 0 (0%)                    | 0 (0%)                |
| Relapse, n (%)           | 5 (35.7%)             | 5 (20%)                   | 10 (25.6%)            |
| Prior to sarcoidosis     | 4 (28.6%)             | 3 (12%)                   | 7 (17.9%)             |
| After sarcoidosis        | 1 (7.1%)              | 2 (8%)                    | 3 (7.7%)              |
| Follow-up after lymphoma, median, mo | 97                   | 29                        | 48                    |
| Interval to sarcoidosis, mo | 41                   | 12                        | 18                    |
| **Sarcoidosis characteristics** |                       |                           |                       |
| Age at diagnosis, median | 50.1                  | 49                        | 49                    |
| Systemic (fever, WL, diaphoresis) | 5 (35.7%)            | 5 (20%)                   | 10 (25.6%)            |
| LN                       | 14 (100%)             | 16 (64%)                  | 30 (76.9%)            |
| Lung                     | 14 (100%)             | 23 (92%)                  | 37 (94.9%)            |
| Mediastinal LN           | 14 (100%)             | 15 (60%)                  | 29 (74.4%)            |
| Pulmonary infiltrates    | 4 (28.5%)             | 9 (36%)                   | 13 (33.3%)            |
| Skin                     | 2 (14.3%)             | 6 (24%)                   | 8 (20.5%)             |
| Arthralgia               | 4 (28.5%)             | 2 (8%)                    | 6 (15.4%)             |
| Muscles                  | 0 (0%)                | 1 (4%)                    | 1 (2.6%)              |
| Uveitis                  | 2 (14.3%)             | 1 (4%)                    | 3 (7.7%)              |
| Hypercalcemia            | 0 (0%)                | 2 (8%)                    | 2 (5.1%)              |
| Spleen                   | 2 (14.3%)             | 0 (0%)                    | 2 (5.1%)              |
| Heart                    | 0 (0%)                | 1 (4%)                    | 1 (2.6%)              |
| CNS                      | 1 (7.1%)              | 0 (0%)                    | 1 (2.6%)              |
| **Treatment, n (%)**     |                       |                           |                       |
| Prednisone               | 4 (28.5%)             | 10 (40%)                  | 14 (35.9%)            |
| NSAID, n (%)             | 1 (7.1%)              | 0 (0%)                    | 1 (2.6%)              |
| IS, n (%)                | 1 (7.1%)              | 1 (4%)                    | 2 (5.1%)              |
| **Clinical response at last follow-up, n (%)** |                       |                           |                       |
| CR                       | 12 (85.7%)            | 20/21 (95.2%)             | 32/35 (91.4%)         |
| PR                       | 0 (0%)                | 0 (0%)                    | 0 (0%)                |
| NR                       | 2 (14.3%)             | 1/21 (4.8%)               | 3/35 (8.6%)           |
| **Radiological response at last follow-up, n (%)** |                       |                           |                       |
| CR                       | 5/13 (38.5%)          | 10/12 (83.3%)             | 15/25 (60%)           |
| PR                       | 3/13 (23.1%)          | 1/12 (8.3%)               | 4/25 (16%)            |
| NR                       | 5/13 (38.5%)          | 1/12 (8.3%)               | 6/25 (24%)            |
| Relapse, n (%)           | 7 (1.7%)              | 1 (4%)                    | 2 (5.1%)              |
| Follow-up after sarcoidosis, median | 28                   | 15                        | 16                    |

BMT = allogeneic bone marrow transplantation, CNS = central nervous system, CR = complete response, DLBCL = diffuse large B-cell lymphoma, HL = Hodgkin lymphoma, HSCT = autologous hematopoietic stem cell transplant, IS = immunosuppressive drugs, LN = lymph nodes, NHL = non-Hodgkin lymphoma, NR = non response, NSAID = nonsteroidal anti-inflammatory drugs, PR = partial response, TCL = T-cell lymphoma, WL = weight loss.

*One patient had both HL and NHL prior to sarcoidosis.
†Including a transformed FL.
‡Including a patient with total body irradiation.
§In addition a patient had a high-grade transformation.
(range, 16–66 years). Twenty patients (51%) had HL and 21 patients (54%) had NHL, with 2 patients having both HL and NHL prior to sarcoidosis. Among patients with NHL, 12 had diffuse large B-cell lymphoma (DLBCL), 3 had follicular lymphoma including 1 transformed follicular lymphoma, 2 had T-cell lymphoma, 1 had mantle cell lymphoma, and 1 patient had NHL without any additional specifications reported. All patients had biopsy-proven lymphoma and none had associated granulomatous reactions on histological examination or had clinical evidence of sarcoidosis (Figure 1).

Lymphoma staging showed that 26/35 (74%) patients were stage 3 or 4. Thirteen out of 39 patients (33%) had “B symptoms” such as night sweats, fever, and weight loss. All patients but 1 had nodal lymphoma involvement, including hilar and/or mediastinal lymphadenopathy in 12/24 (50%) patients who had an available CT-scan at lymphoma diagnosis. No patient had interstitial lung infiltration on thoracic CT. The γglobulin level was normal when available (n = 6) at lymphoma diagnosis, and except for 1 patient with hypercalcemia, calcium levels were normal (n = 7).

**Treatment of Lymphoma and Response to Therapy**

Thirty-seven patients (95%) received chemotherapy, and 2 patients with HL were treated with radiotherapy alone. In addition to chemotherapy, 13 patients (33%) received Rituximab prior to sarcoidosis onset. Radiotherapy was used for 12 patients before sarcoidosis onset (31%), including patients with HL (n = 8), B-cell NHL (B-NHL, n = 3), and T-cell lymphoma (n = 1). Six patients (15%) had intensification treatment followed by autologous hematopoietic stem cell transplant (HSCT) for B-NHL, whereas 2 patients had total body irradiation followed by autologous HSCT (n = 1) or allogenic bone marrow transplantation (BMT, n = 1). One patient also underwent total gastrectomy for a malignant gastric lymphoma (DLBCL) in addition to chemotherapy.

Thirty-six patients (92%) had complete response to treatment, and 3 patients (8%) had a PR followed by relapse a few months later requiring second-line therapy. Overall, 10 patients (26%) had relapse of lymphoma. In addition, a patient treated with chlorambucil for follicular NHL exhibited high-grade transformation after sarcoidosis onset.10 All relapsing patients were treated with chemotherapy except for 1 patient treated with rituximab alone for nodular lymphocytic predominance or type 1 HL (Poppema–Lennert paragranuloma) relapse. Five patients had intensification treatment followed by HSCT for HL relapse. Overall, 10 patients (26%) had a HSCT prior to sarcoidosis onset.

On last evaluation, after a median follow-up of 48 months, 36 patients (92%) had a maintained CR. Two patients had active lymphoma and 1 patient had died after allogenic BMT but without any evidence of malignancy at autopsy.

**Characteristics of Sarcoidosis**

Main characteristics of sarcoidosis diagnosis, treatment, and outcome are summarized in Tables 1, 2, and 3. Median age at sarcoidosis onset was 49 years (range, 23–71 years), and patients were predominantly women (women to men ratio of 2:1).

The median time between lymphoma diagnosis and the sarcoidosis diagnosis was 18 months (range, 1–390 months). When considering the last lymphoma relapse, the median interval until sarcoidosis onset was only 12 months (range, 1–390 months). The lymphoma was in CR at the presentation of sarcoidosis in all but 2 patients. Most patients developed sarcoidosis after the end of chemotherapy.

Sarcoidosis was identified after a systematic CT-scan or 18FDG-PET/CT follow-up evaluation in 18/34 patients (53%), whereas it was identified because of clinical manifestations in 16 patients (47%). Thoracic involvement was noted in 37 patients, with either hilar or mediastinal lymph node enlargement or with pulmonary involvement. At least 29 patients (74%) had mediastinal or hilar lymph node enlargement on chest x-ray, CT-scan, or 18FDG-PET/CT examination. Other manifestations involved the skin in 8 patients (20%) (including erythema nodosum in 3 patients, ichthyosis and panniculitis in 1 patient each), constitutional symptoms (fever, night sweats, and weight loss) in 10 patients (26%), joints in 6 patients (15%), eyes with uveitis in 3 patients (8%), spleen in 2 patients (5%), and heart, muscles, and central nervous system (myelitis and meningitis) in 1 patient each (3%).

Two patients had hypercalcemia that was severe in 1 case leading to acute renal failure. LDH level was normal at sarcoidosis onset in all but 1 patient. ACE level was elevated (>1.5 upper limit of normal) in 5 cases (13%). Two patients had increased γglobulins, and 7 patients had lymphopenia, including mild lymphopenia (1230–1460/μL) in 3 patients and severe lymphopenia (140–660/μL) in 4 patients.

Histological confirmation was obtained from lymph node biopsy in 22 patients (56%) including mediastinal lymph nodes in 17 patients (44%), transbronchial lung biopsy in 5 patients (13%), skin biopsy in 5 patients (13%), open lung biopsy in 4 patients (10%), bone marrow biopsy in 3 patients (8%), minor salivary gland biopsy in 2 patients (5%), and bronchial wall biopsy, lacrimal gland biopsy, and muscle biopsy in 1 case each (3%) (Figure 1).

**Treatment of Sarcoidosis and Response to Therapy**

16 patients (41%) received first-line treatment for sarcoidosis, including oral corticosteroids in 14 patients at a median dose of 40 mg/d (range, 20–60 mg/d), and hydroxychloroquine (HCQ) associated with nonsteroidal anti-inflammatory drugs (NSAID) for arthralgia in 1 case. One patient received only inhaled corticosteroids.

Overall response to the treatment was good; 12/16 (75%) patients experienced clinical CR. Four patients were classified as nonresponders but the assessment of response to therapy was lacking for 3 of these patients. Six patients had radiological CR, 3 had a PR, and 1 had no radiological response (radiological response was not available for 6 patients) (Figure 2). The median duration of corticosteroid treatment was 5.25 months (range, 1–10 months).

Only 2 patients required second-line treatment after sarcoidosis relapse, 4 and 46 months after the first disease flare, respectively. One patient received cyclophosphamide and then methotrexate for severe neurological involvement (myelitis and meningitis), whereas the other received azathioprine for cardiac involvement.

After a median follow-up of 16 months after sarcoidosis onset, 32/35 patients (91%) had no clinical manifestations of sarcoidosis, whereas 15/25 patients (60%) had no radiological evidence of sarcoidosis and 4/25 (16%) had a radiological PR. Of the 3 patients with persisting clinical symptoms of sarcoidosis, 1 had myalgia and asthma, 1 had arthralgia, and 1 patient died because of pulmonary fibrosis shortly after an allogenic HSCT.
without any evidence of sarcoidosis or malignancy at autopsy. Ten patients still had radiological findings of sarcoidosis on last follow-up, consisting of lymph node enlargement for most patients.

FIGURE 1. Histological characteristics of lymphoma and sarcoidosis. Spleen (A, B, and D) and bone marrow biopsy (C) of patient 1 showing DLBCL. Microscopic analysis of splenic nodules revealed diffuse large irregular lymphoid cells (A and B, HES × 2 and × 20, respectively). Bone marrow biopsy showed an infiltration of irregular lymphoid cells with the same phenotype as the lymphomatous cells in the spleen (C, Giemsa × 20). CD20 immunostaining confirmed that lymphomatous cells in the spleen were B cells (D, ×10). Mediastinal lymph node biopsy realized 8 month later (E, HES × 2; F and G, HES ×10; H, HES ×20) displayed characteristic features of sarcoid granuloma: noncaseating small granulomatous lesions (stars), consisting of epithelioid cells without evidence of mycobacterial infection. Several giant multinucleated cells are shown on panel G (arrowheads). DLBCL = diffuse large B-cell lymphoma.

DISCUSSION

The sarcoidosis-lymphoma syndrome described by Brincker was established on the basis of 2 different studies. In a Danish registry of patients with respiratory sarcoidosis,
lymphoma occurred 11.5 times more frequently than expected in the general population. Second, Brincker reviewed 46 cases of lymphoma occurring in patients with sarcoidosis. He reported only 2 cases in which lymphoma preceded sarcoidosis with an additional 2 cases in a subsequent study. The evidence of the sarcoidosis-lymphoma syndrome relied on several findings. First, lymphoma occurred almost always after sarcoidosis with a short median interval of 24 months. Second, patients with the sarcoidosis-lymphoma syndrome were significantly older (median age, 41 years) by 10 years than unselected patients with sarcoidosis. Third, HL occurred more frequently than expected from epidemiological data. Overall, there were 5.5 times more cases of lymphoma observed in patients with sarcoidosis than in the general population. In the present study, we describe a similar association of sarcoidosis and lymphoma, with the particularity of sarcoidosis following lymphoma.

Initially, cases of sarcoidosis following lymphoma were disregarded by Brincker as being a random association. In the present work, we provide some findings that raise the question of a nonfortuitous association. As in Brincker’s study, we report that patients’ median age at sarcoidosis diagnosis was significantly older than the median age in unselected sarcoidosis patients (49 years in our study vs 31 years in unselected sarcoidosis patients). Strikingly, patients with sarcoidosis occurring after

FIGURE 2. Radiological evolution of lymphoma and sarcoidosis. Positron Emission Tomography/Computerized Tomography (18FDG-PET/CT) of patient 1 at lymphoma diagnosis (A), lymphoma remission after diagnostic splenectomy and chemotherapy (B) and at sarcoidosis diagnosis 2 months later (C). Black arrow indicates the occurrence of moderately hypermetabolic (SUVmax = 3.5) hilar lymphadenopathy at sarcoidosis onset. CT scan at sarcoidosis diagnosis of patient 1 (D and E) shows micronodules in the middle lobe (D) and a 19 mm hilar enlarged lymph node (white arrow, panel E). Panel F and G are 18FDG-PET/CT evaluations of patient 2 at sarcoidosis diagnosis (F) and at last follow-up, 6 months after introduction of steroid treatment (panel G) showing a very good PR. PR = partial response, SUV = standardized uptake value.
lymphoma are even older than patients with the sarcoidosis-lymphoma syndrome. The time interval between lymphoma and sarcoidosis was short, with a median delay of 18 months. This interval is even shorter than the 24 months first described by Brincker\textsuperscript{5,31} in the Danish registry or than the 95 months he later reported. Furthermore, if lymphoma relapse is taken into account, the median delay until sarcoidosis onset fell to 12 months, which supports a causal relationship. Such a short interval could also imply an undiagnosed preexisting sarcoidosis, but sarcoidosis followed lymphoma or lymphoma relapse by <6 months for only 2 patients. Alternatively, it is possible that a granulomatous reaction concomitant with the lymphoma was in fact initially present. Besides lymph node involvement, some patients later developed systemic sarcoidosis with general symptoms and skin or eye involvement, which are not unusual features of sarcoid-reaction accompanying lymphoma.\textsuperscript{2} Finally, differentiating sarcoidosis and sarcoid-like reactions may have been difficult for some patients, in particular those with few or no clinical symptoms. Sarcoïd-like reactions refer to the development of noncaseating granulomas in patients who do not fulfill the criteria for systemic sarcoidosis, usually occurring most commonly in oncology patients in the lymph nodes draining a malignant tumor. Our findings that mediastinal or hilar lymph node enlargement was present in at least 74% of patients at sarcoidosis onset, including patients who initially did not have lymphomatous mediastinal lymph nodes, strongly argue for diagnosis of sarcoidosis rather than sarcoid-like reactions.

Sarcoidosis developed shortly after partial or complete hematological response in most patients. It might be argued that the development of sarcoidosis is believed to be related to an excessive immune response against the lymphoma cells. This immunological reaction seems to be correlated with a good prognosis because 92% of patients had a hematological CR to chemotherapy, 8% a PR, and 92% were in sustained hematological remission on last evaluation after a median follow-up of 48 months. Although the lymphoma relapsed in 10 patients, only 3 of them did so after sarcoidosis onset. This is consistent with previous findings that sarcoid-like reactions are associated with a better prognosis in patients with HL.\textsuperscript{3,34} Some authors previously proposed that granulomatous inflammation in the sarcoid-like reaction can be thought of as an immunological hypersensitivity reaction to tumor-derived antigens.\textsuperscript{7} However, because all patients received chemotherapy, radiotherapy, or rituximab, sarcoidosis could also be a reaction to such treatment. However, patients received a very wide variety of different chemotherapy; radiotherapy was used for only 31% of patients, and only 13 patients (33%) received rituximab. Moreover, some patients treated with radiotherapy presented with sarcoid reaction outside the radiotherapy field, had peripheral skin lesions, uveitis, or constitutional symptoms. Some treatments are known to trigger sarcoidosis such as interferon-\(\alpha\),\textsuperscript{35} anti-tumor necrosis factor \(\alpha\),\textsuperscript{36} but patients receiving those treatments were excluded from our study. In addition, radiotherapy and bleomycin, which are frequently used for the treatment of HL can induce lung fibrosis but not granulomatous reactions. Finally, it would be unlikely for a patient with preexisting sarcoidosis to have a disease flare after chemotherapy. Indeed, chemotherapy is very often accompanied by corticosteroids, the major treatment of sarcoidosis.

The main clinicoradiological presentation of sarcoidosis following lymphoma was the unexpected occurrence of hypermetabolic mediastinal or hilar lymphadenopathies following CR after chemotherapy or radiotherapy, frequently in asymptomatic patients. Constitutional symptoms, skin involvement, or uveitis were the most frequently associated symptoms. Therefore, it is very important for clinicians to be aware that sarcoidosis is an alternative diagnosis to lymphoma relapse when confronted with the reoccurrence of hypermetabolic mediastinal or hilar lymphadenopathies on an \(^{18}\)FDG-PET/CT evaluation in a patient with lymphoma. In a previous study, 151 patients with mediastinal lymphoma (57 HL and 94 aggressive NHL) were followed-up with an \(^{18}\)FDG-PET/CT evaluation. Out of the 30 patients who had a suspected relapse on the \(^{18}\)FDG-PET/CT and underwent systematic biopsy for confirmation, only 17 (57%) had confirmed histological relapse, 9 had benign fibrosis, 1 had an unrelated neoplastic condition, and 3 patients (10%) had sarcoid-like granulomatosis (not included in the current study for lack of specific data).\textsuperscript{28} Another study evaluated the prevalence of sarcoid-like reaction to malignancy detected by using \(^{18}\)FDG-PET/CT assessment. Sarcoïd-like reaction was initially suspected in 23/2048 (1.1%) \(^{18}\)FDG-PET/CT evaluation and confirmed in 13 patients (0.6%), including a patient with a suspected HL relapse (not included in the current study for lack of specific data).\textsuperscript{29} In a third study, out of 49 suspected lymphoma relapse on \(^{18}\)FDG-PET/CT follow-up evaluation of 103 patients, 7 patients had alternative diagnosis with 1 case of sarcoidosis.\textsuperscript{30} Sarcoïd reactions following a lymphoma might be mistaken on CT-scan or \(^{18}\)FDG-PET/CT evaluation for lymphoma relapse. This emphasizes the importance of systematic histological confirmation of lymphoma relapse to avoid unnecessary and potentially harmful intensification treatments.

The majority of cases of sarcoidosis occurring after lymphoma seem to be of mild intensity or even self-healing. Indeed, only 16 patients (41%) required treatment and 14 (36%) oral corticosteroids. Only 2 patients required immunosuppressive therapy for severe manifestations with probable cardiac involvement in 1 case and central nervous system involvement in the other. Even if only 60% of patients (15/25) had a complete radiological response on last evaluation, overall clinical response was excellent with 91% of patients being in complete clinical response. Several patients were asymptomatic at sarcoidosis presentation, therefore, it is possible that the CT-scan or \(^{18}\)FDG-PET/CT evaluation in lymphoma follow-up might result in overdiagnosis of cases of self-healing sarcoidosis that would otherwise have gone unnoticed. Therefore, sarcoidosis following lymphoma could be a fortuitous association with sarcoidosis in asymptomatic patients being simply overdiagnosed because of the radiological follow-up of patients with lymphoma. Because at the opposite we also report cases of genuine sarcoidosis following lymphoma, we can make the assumption that self-healing cases of sarcoidosis accompany the immune response to lymphoma and are underdiagnosed. This study was not designed to determine the causal relationship between sarcoidosis and lymphoma. Indeed, it is a retrospective study combining 14 cases for which we recorded the data from patients’ medical records using a standardized form, and 25 patients reported in the literature for whom we had only limited data available. Therefore, a larger study assessing prospectively the occurrence of sarcoidosis in patients with and without lymphoma would be needed to conclude definitively that there is a nonfortuitous association. In conclusion, sarcoidosis may occur after lymphoma diagnosis, and this association seems to be nonfortuitous. Patients with sarcoidosis following lymphoma are older than unselected sarcoidosis patients, have a short interval between lymphoma and sarcoidosis presentation, and frequently have a mild form of sarcoidosis. These patients may have an
aberrant immunological reaction accompanying the immune response to the lymphoma cells, but the causal relationship between lymphoma and sarcoidosis remains to be determined by further epidemiological studies. Finally, we emphasize the necessity to rely on histological confirmation of a lymphoma relapse if suspected on 18FDG-PET/CT examination.

REFERENCES

1. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet. 2014;383:1155–1157.
2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–755.
3. Brincker H. The sarcoidosis-lymphoma syndrome. Br J Cancer. 1986;54:467–473.
4. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006;98:1321–1330.
5. Kadin ME, Glatstein E, Dorfman RF. Clinicopathologic studies of 117 untreated patients subjected to laparotomy for the staging of Hodgkin’s disease. Cancer. 1971;27:1277–1294.
6. Kim H, Dorfman RF. Morphological studies of 84 untreated patients subjected to laparotomy for the staging of non-Hodgkin’s lymphomas. Cancer. 1974;33:657–674.
7. Brincker H. Sarcoïd reactions in malignant tumours. Cancer Treat Rev. 1986;13:147–156.
8. Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007;92:771–777.
9. Kornacker M, Kraemer A, Leo E, et al. Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin’s lymphoma: report of two cases. Ann Hematol. 2002;81:103–105.
10. Goonaratne L, Nagi W, Lim Z, et al. Sarcoidosis and haematological malignancies: is there an association? Br J Haematol. 2008;141:260–262.
11. Maayan H, Ashkenazi Y, Nagler A, et al. Sarcoidosis and lymphoma: case series and literature review. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:146–152.
12. De Henricourt E, De Boeck K, Hilte F, et al. Sarcoidosis and sarcoïd-like reaction following Hodgkin’s disease. Report of two cases. Mol Imaging Biol. 2003;5:15–19.
13. Li W, Holdeman K, Laurin JA, et al. Sarcoidosis mimicking recurrent lymphoma. Am J Hematol. 2012;87:711–712.
14. Subbiah V, Ly UK, Khiyami A, et al. Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin’s lymphoma: a case report. J Med Case Reports. 2007;1:148.
15. Fallanca F, Picchio M, Crivellaro C, et al. Unusual presentation of sarcoïd-like reaction on bone marrow level associated with mediastinal lymphadenopathy on (18)F-FDG-PET/CT resembling an early recurrence of Hodgkin’s Lymphoma. Rev Esp Med Nucl Imagen Mol. 2012;31:207–209.
16. Suen JS, Forse MS, Hyland RH, et al. The malignancy-sarcoidosis syndrome. Chest. 1990;98:1300–1302.
17. van den Berg, Fickers M, Theunissen P, et al. Pulmonary sarcoïd-like granulomata in a patient treated for extraluminal Hodgkin’s disease. Respir Int Rev Thorac Dis. 1997;64:114–117.
18. Merchant TE, Filippa DA, Yahalom J. Sarcoidosis following chemotherapy for Hodgkin’s disease. Leuk Lymphoma. 1994;13:339–347.
19. Sawhney M, Sharma YK, Gera V, et al. Ithchysiform sarcoidosis following chemotherapy of Hodgkin’s disease. Indian J Dermatol Venereol Leprol. 2003;69:220–222.
20. Sonet A, Graux C, Nollevaux M-C, et al. Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol. 2007;86:9–15.
21. Paydas S, Yayvuz S, Disel U, et al. Granulomatous reaction after chemotherapy for Hodgkin’s disease. Leuk Res. 2002;26:967–970.
22. Nouwynck C, Tjeka R, Lustman F. Progressive mediastinal widening after therapy for Hodgkin’s disease. Association of Hodgkin’s disease with sarcoidosis. Acta Clin Belg. 1996;51:118.
23. Nakamura Y, Kurihara N, Sato A, et al. Muscle sarcoidosis following malignant lymphoma: diagnosis by MR imaging. Skeletal Radiol. 2002;31:702–705.
24. Brincker H. Sarcoidosis and malignancy. Chest. 1995;108:1472–1474.
25. Farrell AM, Henry K, Woodrow D, et al. Cutaneous granulomas associated with high-grade T-cell non-Hodgkin’s lymphoma. Br J Dermatol. 1999;140:145–149.
26. Ozer O, Eskazan AE, Ar MC, et al. Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. J Med Case Reports. 2009;3:7306.
27. Hollister D Jr, Lee MS, Eisen RN, et al. Variable problems in lymphomas: CASE 2. Sarcoidosis mimicking progressive lymphoma. J Clin Oncol. 2005;23:8113–8116.
28. Chowdhury FU, Sheerin F, Bradley KM, et al. Sarcoïd-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin Radiol. 2009;64:675–681.
29. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
30. Cheson BD, Pfister B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2006;25:579–586.
31. Brincker H, Wilbek E. The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer. 1974;29:247–251.
32. Horwitz O, Payne PG, Wilbek E. Epidemiology of sarcoidosis in Denmark. Dan Med Bull. 1967;14:178–182.
33. Sacks EL, Donaldson SS, Gordon J, et al. Epithelioid granulomas associated with Hodgkin’s disease: clinical correlations in 55 previously untreated patients. Cancer. 1978;41:562–567.
34. O’Connell MJ, Schimpff SC, Kirschner RH, et al. Epithelioid granulomas in Hodgkin disease. A favorable prognostic sign? JAMA. 1975;233:886–889.
35. Ramos-Casals M, Mañá J, Nardi N, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore). 2005;84:69–80.
36. Delen CI, Monnier A, Claudepierre P, et al. Sarcoïd-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatol Oxf Engl. 2009;48:883–886.